Global HIV Infection Drug Market & Pipeline Insight

Description: The rate of HIV infection and the number of deaths due to AIDS has been on a declining note at a positive rate across the globe. It has been estimated that the death rate reduced from 2.3 million in 2005 to 1.5 in 2013, with the rates for children being even much lower. A major cause for such drastic changes in the infection rates has been the improved access to antiretroviral drugs and therapy in recent years. The access to these drugs and therapy has improved significantly, particularly in many developing countries where these drugs and treatments were previously not available at all. At present these solutions have been made accessible and affordable also.

However, a major trend observed in this market has been that although the HIV infection rates are falling, the number of new patients being affected by the virus is increasing. With all the conscious efforts undertaken by all the related organizations and stakeholders, it is expected that by 2015, significant investments would be recorded in this field with the WHO setting an aim to treat close to 15 million HIV patients.

In terms of the market, with the rising popularity of this disease and the growing efforts to combat its spread, it is most likely that an increasing number of companies would enter this market, which would, in the long run, reduce the overall cost of drugs owing to increased competition among the players. Additionally, economies of scale would also be a major factor driving down the cost of drugs targeted for the HIV virus infected people. This in turn would make the drugs and treatment options more affordable.

It is expected that in the next 5-8 years, the pharmaceutical companies would focus more on the development of a successful efficient vaccine to control the spread of this disease. The allocation of resources should necessarily reflect ongoing, strategic prioritization of candidates in the pipeline. With the progress of trials and accumulation of information on the safety and efficacy of new products, there is an urgent demand for strategizing the product pipelines and the prioritization of the decisions. There needs to be complete scrutiny of every single technological area of HIV prevention R&D so as to reflect the best methods of channelizing the funds which are limited in nature. The funds need to be specifically directed towards only those products and approaches which have a high probability of succeeding, instead of those which are less promising.

“Global HIV Infection Drug Market & Pipeline Insight” Report Highlight:

Global HIV Infection Drug Market Overview & Incidence Scenario
FDA & EMA Regulation for Development of HIV Drug
Global HIV Infection Drug Clinical Pipeline by Phase, Company & Country
Global HIV Clinical Pipeline: 315 Drugs in Development Phases
 Majority HIV Drug in Preclinical Phase: 144 Drugs
Marketed HIV Drugs: 37
Suspended & Discounted HIV Drug in Clinical Pipeline: 539 Drugs

Contents:
1. Global HIV Infection Drug Market Overview
   1.1 Global HIV Incidence Scenario
   1.2 Market Overview: Global & Regional
   1.3 Clinical Pipeline Overview

2. Global HIV Infection Drug Market Dynamics
   2.1 Favorable Market Drivers
   2.2 Market Challenges to be Resolved
   2.3 Future Opportunity Outlook

3. FDA Regulatory Framework for Development of HIV Vaccine
3.1 Development of Preventive HIV Vaccines for Use in Paediatric Populations
3.2 Guidance for Submitting HIV Resistance Data
3.3 HIV Resistance Testing in Antiretroviral Drug Development
3.4 HIV-1 Infection: Developing Antiretroviral Drugs for Treatment

4. EMA Regulatory Framework for Development of Medicinal Products For Treatment Of HIV Infection

5. Global HIV Infection Drug Clinical Pipeline by Phase, Company & Country
5.1 Phase Unknown
5.2 Research
5.3 Preclinical
5.4 Clinical
5.5 Phase-0
5.6 Phase-I
5.7 Phase-I/II
5.8 Phase-II
5.9 Phase-III
5.10 Preregistration
5.11 Registered

6. Marketed HIV Drug Clinical Profile by Company & Country

7. Suspended & Discontinued HIV Drugs in Clinical Pipeline by Phase, Company & Country
7.1 No Development Reported
7.2 Discontinued
7.3 Suspended

8. Competitive Landscape
8.1 Antigen Express
8.2 Bionor Pharma
8.3 FIT Biotech
8.4 Gilead Sciences
8.5 GeoVax
8.6 GenVec
8.7 Glaxo Smithkline
8.8 Immune Response BioPharma
8.9 Inovio Pharmaceuticals
8.10 Novartis
8.11 Sanofi Pasteur

List of Figures:

Figure 1-1: People Living With HIV Infection (Million), 2009-2014
Figure 1-2: New Incidence of HIV Infection (Million), 2009-2012
Figure 1-3: People Living With HIV Infection by Region (%), 2012
Figure 1-4: People Accessing Treatment for HIV Infection (Million), 2009-2012
Figure 1-5: Global - HIV/AIDS Therapeutics Market (US$ Billion), 2013-2018
Figure 1-6: Global - HIV Infection Drug Pipeline by Phase (%), 2014
Figure 1-7: Global - HIV Infection Drug Pipeline by Phase (Number), 2014
Figure 1-8: Global - No Development Reported in HIV Infection Drug in Pipeline by Phase (%), 2014
Figure 1-9: Global - No Development Reported in HIV Infection Drug in Pipeline by Phase (Number), 2014
Figure 1-10: Global - Discontinued HIV Infection Drug in Pipeline by Phase (%), 2014
Figure 1-11: Global - Discontinued HIV Infection Drug in Pipeline by Phase (Number), 2014
Figure 1-12: Global - Suspended HIV Infection Drug in Pipeline by Phase (%), 2014
Figure 1-13: Global - Suspended HIV Infection Drug in Pipeline by Phase (Number), 2014

Order by Fax - using the form below
Order by Post - print the order form below and send to
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Global HIV Infection Drug Market & Pipeline Insight
Web Address: http://www.researchandmarkets.com/reports/2910858/
Office Code: SCBR6SUP

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Product Format</th>
<th>Quantity</th>
<th>Cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td>☐</td>
<td>USD 2400</td>
</tr>
<tr>
<td>CD-ROM</td>
<td>☐</td>
<td>USD 2600 + USD 58 Shipping/Handling</td>
</tr>
<tr>
<td>Hard Copy</td>
<td>☐</td>
<td>USD 3000 + USD 58 Shipping/Handling</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td>☐</td>
<td>USD 4200</td>
</tr>
</tbody>
</table>

* Shipping/Handling is only charged once per order.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: ☐ Mr ☐ Mrs ☐ Dr ☐ Miss ☐ Ms ☐ Prof
First Name: ____________________________ Last Name: ____________________________
Email Address: * ____________________________
Job Title: ____________________________
Organisation: ____________________________
Address: ____________________________
City: ____________________________
Postal / Zip Code: ____________________________
Country: ____________________________
Phone Number: ____________________________
Fax Number: ____________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World